Strategic Partnerships Leverage recent collaborations with Leica Biosystems and Indica Labs to position Lunit as a preferred AI pathology partner for PD-L1 and emerging biomarkers, highlighting joint go-to-market opportunities and integrated AI solution demos for pathology workflows.

Clinical Validation Emphasize extensive validation across 100+ peer‑reviewed publications and deployment in 3,500+ sites to build credibility for prospective customers seeking evidence-based AI for radiology and oncology screening, accelerating test drives and pilots.

Expand Radiology Suite Target radiology departments and imaging centers seeking AI triage and advanced mammography/DBT solutions, offering bundled deployments of INSIGHT CXR, MMG, and DBT with pilot programs in high-volume sites to demonstrate diagnostic uplift.

Precision Oncology Capitalize on participation in ASCO and AACR programs to prospect cancer centers and research groups for biomarker quantification and spatial tumor microenvironment analysis, linking AI insights to enrollment-ready biomarker-driven trials.

Global Scale & Funding Position Lunit as a mature, globally deployed AI platform with substantial revenue and steady funding, enabling enterprise-scale deployments, managed services, and long-term support contracts across US and international markets.